Molecular Oncology
Volume 2, Issue 1 , Pages 20-32, June 2008

Trends in the global funding and activity of cancer research☆

  • Seth Eckhouse

      Affiliations

    • European Cancer Research Managers Forum, London, UK
    • ,
  • Grant Lewison

      Affiliations

    • School of Library, Archive and Information Studies, University College London, Gower Street, London WC1E 6BT, UK
    • ,
  • Richard Sullivan

      Affiliations

    • European Cancer Research Managers Forum, London, UK
    • Department of Social Policy (Population, Health and Society), London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK
    • Corresponding Author InformationCorresponding author. Department of Social Policy (Population, Health and Society), London School of Economics and Political Science, Houghton Street, London WC2A 2AE, UK. Tel.: +44 7720398401.
    • RS was formally Director of Clinical Programmes at Cancer Research UK and is now a Consultant at PHG Foundation, Cambridge.

Received 14 March 2008; accepted 17 March 2008. published online 23 April 2008.

Abstract 

Cancer research has carved an astonishing trajectory giving rise to a multi billion euro global network covering most domains of science and including all manner of research funders from industry to government and philanthropic funders. We have estimated that in 2004/2005 the global spend on cancer research was 14,030 million euros, with the USA, dominated by the NCI (c. 83%) accounting for the largest absolute spend. This is between 2 and 3 times the level of per capita spend compared to EU-15 and Europe, respectively. In Europe, the UK is at comparable levels of spend compared to the USA. Funding for cancer research in Europe is split almost 50:50 between philanthropic and governmental sources. Cancer research productivity in terms of outputs (publications) is slightly greater in Europe compared to the USA with an increasing trend towards more applied (clinical) outputs. Both the USA and Europe have equally strong industry-supported output levels.

Keywords: Cancer, Policy, Funding, Activity, Pharmaceutical, Outputs

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

☆ This work was supported by European Cancer Research Managers Forum (ECRM) and a previous EU 5th Framework grant (QLG1-CT-2002-30203/ECRM).

PII: S1574-7891(08)00040-9

doi:10.1016/j.molonc.2008.03.007

Molecular Oncology
Volume 2, Issue 1 , Pages 20-32, June 2008

Article Tools

* Image Usage & Resolution